Background
HIV and unintended pregnancy remain intersecting global burdens on women’s health. Adherence challenges limit the effectiveness of oral HIV PrEP and contraception. We propose to develop an ultra-long-acting (ULA) in-situ forming implant (ISFI) multipurpose prevention technology (MPT) co-formulating dolutegravir (DTG) and levonorgestrel (LNG) as a once-yearly injectable to reduce dosing burden and enhance compliance.
Methods
Two 1mL injections of DTG ISFI (350 mg/mL; ~50 mg/kg) were administered to female rhesus macaques (n=2), with weekly monitoring of implant site reactions and plasma DTG levels over 35 days. Based on PK data in macaques, dose optimizations were performed to develop ISFIs with increased DTG concentrations to provide sustained DTG release (>1 yr). BALB/c mice were used to evaluate the PK of optimized formulations (n=5/group). In mice, single subcutaneous (SC) injections (50-100 µL) of ISFI formulations (F1, F2, F3) with varying DTG concentrations (350, 530, 720 mg/mL, respectively) were evaluated over 180 days. SC tissue was collected from injection sites at euthanasia and scored for local inflammation. Plasma was collected to assess systemic inflammatory response. An ISFI co-formulated with DTG/LNG (630/50 mg/mL) was evaluated to assess in vitro release kinetics.
Results
DTG ISFIs (350 mg/mL; F1) provided sustained plasma DTG in macaques for 35 days (Fig. 1A). Using previously published DTG clearance estimates from cynomolgus macaques for plasma PK deconvolution, estimated DTG absorption rates were 2337-6270 μg/day. Assuming 350 mg DTG/implant and zero-order absorption, this formulation should last for 116-350 days. One macaque experienced transient implant site reaction by week 2 that resolved following treatment. In mice, DTG ISFIs were well-tolerated, and increasing DTG loading produced PK profiles similar to F1 (Fig. 1B) with projected longer release duration. Median plasma DTG levels during the first 6 months were 5006, 4178, and 3900 ng/mL for F1, F2, and F3, respectively (Fig 1B). Ongoing in vitro studies of co-formulated DTG/LNG ISFIs demonstrate sustained zero-order release over 60 days.
Conclusions
PK studies conducted across two animal species confirmed in vivo release of DTG from ISFIs. PK data of optimized DTG ISFI formulations highlight the potential to provide long-acting delivery of DTG (≥1 year). Taken together, these findings support the development of ISFIs as a once-yearly injectable MPT for preventing HIV infections and unintended pregnancy.
Table or Figure
